CD3-Antibody Therapy in New-Onset Type 1 Diabetes Mellitus

To the Editor: We urge caution regarding the conclusion of Keymeulen et al. (June 23 issue) 1 in reporting their study of CD3-antibody therapy for new-onset type 1 diabetes mellitus that treatment with ChAglyCD3 preserves residual beta-cell function. Differences in C-peptide levels between the study groups at six months suggest a benefit of treatment. However, increases in C-peptide levels in treated patients at 6 months, with decreases in C-peptide levels in controls, appear to account for most of the improvement in the treated group at 18 months. After six months, the rate of C-peptide loss is almost identical in both groups. . . .